跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Can AI Discover New Drugs? A High-Level Overview

1Why Drug Discovery Is Hard, and Where AI Fits2How AI Learns From Molecules and Proteins3Finding and Validating a Biological Target4Designing Molecules: Generative AI and Virtual Screening5From Hit to Lead: Optimizing Properties With AI6What AI Still Cannot Do7Judging the Claims: Real Successes, Failures, and Open Questions
What AI Still Cannot Do

The Gap Between a Prediction and a Person

4 / 4
Look at the two ends of the bridge. On one side, a prediction about a molecule in a defined assay. On the other, whether a person gets better. The bridge between them is not a straight line — it is a series of steps, and each step is a place where the prediction can break. Absorption, metabolism, the immune system, other conditions, other drugs, genetic background. The model was never trained on most of that. So the score is not a small version of the clinical answer; it is a different kind of claim entirely. The trial is what converts one into the other, and nothing before the trial can do that job.
0:00 / 0:00

A model can be right about everything it was asked and still be wrong about the patient. The distance between a computational result and a clinical outcome is crossed by biology that no dataset fully represents.

Start with what the model actually predicts. It predicts a property of a molecule — binding, solubility, a toxicity flag — measured in a defined assay, often in cells or in animals. That is a real result. But a human body is not an assay. It has variable absorption, competing metabolic pathways, an immune system, other diseases, other drugs, and a genetic background that differs from every training sample.

Each step away from the assay adds a source of failure the model never saw. A compound that binds beautifully in a test tube may never reach the target organ. A toxicity flag that was clean in a cell line may not capture an effect that only appears after months in a whole organism. A result that holds in one population may not hold in another, because the training data underrepresented that group.

The decisive test is therefore not the model's score. It is whether the compound works in humans, and that question can only be answered by running the trial. Everything before that point — every prediction, every ranking, every in-silico result — is a reason to run the experiment, not a substitute for it. This is the same prediction-versus-experiment line from the previous chapter, extended to its final and most consequential step.

上一页4 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion